Breast core needle biopsy diagnosis and personalized treatment: navigating pitfalls and challenging lesions
Histopathology · 2026-11 · 89 (5) · 758-778
DOI: 10.1111/his.70186 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Histopathology, online erschienen am 03.06.2026. Verfasst von Emad A Rakha und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Nottingham, Nottingham, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Biopsy, Large-Core Needle, Precision Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
Most breast lesions can be diagnosed accurately on core needle biopsy (CNB); however, certain entities remain diagnostically challenging due to limited tissue sampling, morphological overlap with other lesions, unusual immunoprofiles or lack of reliable ancillary markers. These challenges are compounded by modern clinical requirements, particularly the increasing shift towards neoadjuvant therapy (NAT) where a definitive diagnosis is required before surgical excision. Misclassification may have clinically significant consequences, including inappropriate initiation of NAT or undertreatment of aggressive disease. This review provides a structured diagnostic approach to breast lesions that are particularly prone to misinterpretation on CNB. We discuss malignant lesions that should not trigger NAT, while highlighting the diagnostic and reporting pitfalls associated with microinvasive disease, where definitive confirmation of established invasion is often elusive on limited material. Key morphological clues, immunohistochemical strategies and the selective role of molecular testing in resolving differential diagnoses of overlapping and challenging lesions are emphasized. A transparent reporting style that acknowledges uncertainty, together with multidisciplinary collaboration and selective expert consultation, optimizes patient management. The review aims to provide practical guidance, avoid diagnostic pitfalls and promote safe decision‐making when dealing with complex breast lesions on limited biopsy material.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, University of Nottingham, Nottingham, UK.
- Department of Pathology, Hamad Medical Corporation, Doha, Qatar.
- Irish National Breast Screening Programme and Department of Histopathology, St. Vincent's University Hospital, and School of Medicine, University College, Dublin, Ireland.
- Luma Medical Centre, Royal Square Medical Centre, Singapore, Singapore.
- Discipline of Pathology, School of Medicine, University of Galway, Galway, Ireland.
ORCID-Profile: Emad A Rakha, Grace Callagy
Zitieren
APA
Rakha, E. A., Quinn, C., Tan, P. H., & Callagy, G. (2026). Breast core needle biopsy diagnosis and personalized treatment: navigating pitfalls and challenging lesions. Histopathology, 89(5), 758-778. https://doi.org/10.1111/his.70186
Vancouver
Rakha EA, Quinn C, Tan PH, Callagy G. Breast core needle biopsy diagnosis and personalized treatment: navigating pitfalls and challenging lesions. Histopathology. 2026;89(5):758-778. doi:10.1111/his.70186
BibTeX
@article{Rakha2026,
author = {Rakha, Emad A and Quinn, Cecily and Tan, Puay Hoon and Callagy, Grace},
title = {Breast core needle biopsy diagnosis and personalized treatment: navigating pitfalls and challenging lesions},
journal = {Histopathology},
year = {2026},
volume = {89},
number = {5},
pages = {758--778},
doi = {10.1111/his.70186}
}
EUVIMED